Abstract: Provided herein are 1-aryl or 1-heteroarylsubstituted phenanthrene diketo acid compounds. These compounds comprise a ?-carboline ring structure substituted at C1 with an aryl or heteroaryl moiety and individually substituted at C3-C8 and N9 with a C1-C4 alkyl, a C1-C4 alkoxy, a C1-C4 alkoxyphenyl, halogen, thiol, alkylthiol, sulfonyl, sulfomainde, amide, substituted amide, ester, nitrile, OH, amino, substituted amine, haloalkyl, haloalkoxy, acyl, or a hydrogen. Also provided are methods for inhibiting proliferation of a cancer cell or for treating a cell proliferative disease by contacting the cancer cell or tumor comprising the same with the compounds provided herein or by administering the compounds to a subject with a cell proliferative disease.
Type:
Application
Filed:
April 26, 2010
Publication date:
December 16, 2010
Inventors:
John K. Buolamwini, Shivaputra Patil, James K. Addo, D. Parker Suttle, Ruiwen Zhang, Zhengxiang Zhu, Sharma Horrick
Abstract: This invention provides alpha-carboline compounds of formula I: wherein R1, R2, R3, R4, R5, and x are as described in the specification. The compounds are useful for treating inflammatory diseases and cancer.
Type:
Application
Filed:
August 19, 2010
Publication date:
December 9, 2010
Applicant:
Millennium Pharmaceuticals, Inc.
Inventors:
Michael E. Hepperle, Julie Fields Liu, R. Scott Rowland, Dilrukshi Vitharana
Abstract: The present invention provides a method of decreasing the level of ubiquitylated protein in a subject, the method comprising administering a heterocyclic compound disclosed herein or a pharmaceutically acceptable salt, hydrate or prodrug thereof to a subject in need thereof.
Type:
Application
Filed:
May 11, 2010
Publication date:
November 25, 2010
Inventors:
Kim Nicholas Green, Eckard Weber, Tilman Oltersdorf, Sharon Rogers, Frank LaFerla
Abstract: A knock-out non-human animal, in particular a mouse, carrying a QPCTL knock-out mutation. Additionally, respective cells and cell lines and methods and compositions for evaluating agents that affect QPCTL, for use in compositions for the treatment of QPCTL-related diseases are disclosed.
Abstract: There is provided a compound of the formula (I?): wherein X is a nitrogen or CRx, Rx is a hydrogen, etc., R1 is an optionally substituted hydrocarbon group, etc., R2 is an optionally substituted hydrocarbon group, etc., ring A is 5- to -8-membered heterocyclic ring, etc., and each of Y1, Y2 and Y3 is an optionally substituted carbon or a nitrogen, etc.; or ‘a salt thereof or a prodrug thereof, which have CRF receptor antagonistic activity and use thereof.
Abstract: The present invention relates to new prop-2-yn-1-amine inhibitors of monoamine oxidase type B activity, pharmaceutical compositions thereof, and methods of use thereof.
Abstract: A means for improving cognitive functions and memory based on hydrogenated pyrido (4,3-b) indoles (variants), a pharmacological means based thereon and a method for the use thereof relate to the use of chemical compounds in the field of medicine and may be used to extend the arsenal of means which can be utilized for substantial enhancement of memory and activation of the learning process, for the treatment of impaired cognitive functions and memory in the elderly and in mild cognitive impairment, in brain trauma, in chronic cerebrovascular insufficiency, in hypoxic encephalopathies, resulting from chronic alcoholism and in delayed development in children. Said task is resolved by the use of hydrogenated pyrido ([4, 3-b]) indoles of formula (1) or formula (2) as means for improving cognitive functions and memory.
Type:
Application
Filed:
November 30, 2007
Publication date:
November 11, 2010
Inventors:
Sergey O. Bachurin, Svetlana I. Gavrilova, Vladimir V. Grigoriev, Bogdan K. Beznosko, Nikolay S. Zefirov
Abstract: The present invention relates to compounds, as well as to compositions, methods and kits comprising such compounds, for use in the treatment or prophylaxis of fibromyalgia, chronic fatigue syndrome, myofascial pain syndrome, Gulf War syndrome and related conditions, wherein the compound is a fatty acid oxidation inhibitor and/or a carbohydrate oxidation activator.
Abstract: The present invention relates to compounds for the inhibition of poly(ADP-ribose) polymerase (PARP). In some embodiments, the compounds have the Formula: wherein the constituent variables are as defined herein. The invention further provides methods for the use of the compounds disclosed herein.
Abstract: The invention relates to a combination comprising vascular disrupting agent (VDA), such as 5,6-dimethylxanthenone-4-acetic acid or a pharmaceutically acceptable salt, ester or prodrug thereof; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
Abstract: The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
Type:
Application
Filed:
December 9, 2008
Publication date:
October 21, 2010
Inventors:
Jonathan R. Young, Jongwon Lim, Michelle R. Machacek, Brandon Mitsuo Taoka, Ryan D. Otte
Abstract: Compositions, methods, and combination therapies for the treatment of cancers, including lymphomas, leukemias, melanomas, lung cancer, and metastatic disease, are provided. Specifically, compositions comprising ligands to Pgrmc1 are disclosed for use in treating and inhibiting tumor growth and progression and inhibition of metastases. The compositions and methods using these ligands can be used alone or in combination with other reagents and cancer treatment modalities.
Type:
Application
Filed:
April 20, 2010
Publication date:
October 21, 2010
Applicant:
University of Kentucky Research Foundation
Abstract: The present disclosure relates to pyridoindolone derivatives of general formula (I): in which R1 to R5 are as defined in the specification, to processes for preparing said derivatives, and to methods of use thereof.
Type:
Grant
Filed:
October 16, 2008
Date of Patent:
October 19, 2010
Assignee:
sanofi-aventis
Inventors:
Bernard Bourrie, Pierre Casellas, Jean-Marie Derocq, Samir Jegham, Yvette Muneaux
Abstract: A method of treating atherosclerosis, dyslipidemias and related conditions is disclosed wherein a therapeutic dose of nicotinic acid, approximately 1 gram, is administered to the patient once daily as a starting dose, and the dose is thereafter raised within a few days or weeks to 2 grams for the duration of therapy. The nicotinic acid may be administered in combination with a selective DP receptor antagonist. The selective DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.
Type:
Application
Filed:
February 5, 2008
Publication date:
October 14, 2010
Inventors:
John F. Paolini, Eseng Lai, Yale B. Mitchel
Abstract: It is an object of the present invention to provide a safe and highly effective preventing or ameliorating agent for skin psoriasis. The present invention provides a preventing or ameliorating agent for skin psoriasis, containing, as an active ingredient, a compound represented by general formula (I) or a salt thereof: (wherein R1, R2, and R3 simultaneously or separately represent a lower alkyl, lower alkenyl, lower alkynyl, aralkyl, araryl, or phenyl group, or a hydrogen atom).
Type:
Application
Filed:
November 12, 2008
Publication date:
October 14, 2010
Applicants:
KYOWA HAKKO BIO CO., LTD., MITSUBISHI GAS CHEMICAL CO., LTD.
Abstract: This invention provides alpha-carboline compounds of formula I: wherein R1, R2, R3, R4, R5, and x are as described in the specification. The compounds are useful for treating inflammatory diseases and cancer.
Type:
Grant
Filed:
February 15, 2007
Date of Patent:
October 12, 2010
Assignee:
Millennium Pharmaceuticals, Inc.
Inventors:
Michael E. Hepperle, Julie Fields Liu, R. Scott Rowland, Dilrukshi Vitharana
Abstract: The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. Also, the invention relates to the discovery of specific compounds and compositions containing that function as bitter taste blockers and the use thereof as bitter taste blockers or flavor modulators in, e.g., coffee and coffee flavored foods, beverages and medicaments. Also, the present invention relates to the discovery of a compound that antagonizes numerous different human T2Rs and the use thereof in assays and as a bitter taste blocker in compositions for ingestion by humans and animals.
Type:
Application
Filed:
February 19, 2010
Publication date:
October 7, 2010
Applicant:
Senomyx, Inc.
Inventors:
Donald S. Karanewsky, Joseph Fotsing, Catherine Tachdjian, Melissa Arellano
Abstract: A pharmaceutical composition is provided that comprises a solid dispersion of implitapide. Such solid dispersions may include implitapide and least one pharmaceutically acceptable excipient. In some embodiments, the disclosed solid dispersions comprise substantially amorphous implitapide.
Abstract: Described herein are formulations and devices for delivering compounds to arthropods and microorganisms within the arthropods. The formulations are generally composed of a sugar and the compound, wherein the compound targets a particular pathogen or other microorganism within the arthropod, kills the arthropod, or a combination thereof.
Abstract: The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition, their use as a medicament, especially for treating a treatment neurodegenerative or haematological disease or condition, and a pharmaceutical composition comprising the compounds.
Type:
Application
Filed:
June 11, 2008
Publication date:
September 23, 2010
Applicant:
NOSCIRA, S.A.
Inventors:
Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Jorge Sanchez-Quesada, Mercedes Alonso Cascon, Laura Rubio Arrieta, Esther Garcia Palomero, Paola Usan Egea
Abstract: The invention relates to tetrahydropyridoindole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions comprising one or more of those compounds and methods of treatment comprising administration of said compounds.
Type:
Application
Filed:
March 16, 2010
Publication date:
September 16, 2010
Applicant:
Actelion Pharmaceuticals Ltd
Inventors:
Anja Fecher, Heinz Fretz, Kurt Hilpert, Markus Riederer
Abstract: The present invention provides tumor cell preparations for use as models of the EMT process for use in the identification of anti-cancer agents, wherein said tumor cell preparations comprise cells of the epithelial tumor cell line CFPAC-1, which are stimulated by receptor ligands to induce EMT, or which have been engineered to inducibly express a protein that stimulates EMT. The present invention also provides methods of identifying potential anti-cancer agents by using such tumor cell preparations to identify agents that inhibit EMT, stimulate MET, or inhibit the growth of mesenchymal-like cells. Such agents should be particularly useful when used in conjunction with other anti-cancer drugs such as EGFR and IGF-1R kinase inhibitors, which appear to be less effective at inhibiting tumor cells that have undergone an EMT.
Type:
Application
Filed:
February 26, 2010
Publication date:
September 2, 2010
Inventors:
Julie Kan, Salam A. Shaaban, Joseph S. Krueger, Maryland Franklin, Robert C. Wild
Abstract: Provided are bis-quaternary ammonium cyclophane compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders.
Type:
Application
Filed:
May 11, 2007
Publication date:
September 2, 2010
Applicant:
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
Inventors:
Peter Crooks, Linda P. Dworskin, Guangrong Zheng, Sangeetha Sumithran, Davis D. Allen, Zhenfa Zheng, Paul Lockman
Abstract: This application relates to a compound of Formula ! (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an antagonist of receptor CRTH2, as well as a process for its preparation and intermediates therefor.
Abstract: This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
Type:
Application
Filed:
October 30, 2009
Publication date:
August 26, 2010
Inventors:
David T. HUNG, Andrew Asher Protter, Rajendra Parasmal Jain, Sarvajit Chakravarty
Abstract: The present invention relates to compounds of the formula (I) wherein R1, R2, R3, R4, R5, X1, X2, X3, X4, n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXR? and/or LXR? agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.
Abstract: The present invention provides: a pharmaceutical composition for inhibiting amyloid-? protein accumulation comprising a compound represented by the formulas including (I) or a pharmaceutically acceptable salt thereof; a method for inhibiting amyloid-? protein accumulation, comprising a step of administering an effective amount of the compound represented by the formulas including (I) or a pharmaceutically acceptable salt thereof to a mammal which may be diagnosed with an amyloid-? protein-related disease; and so on.
Abstract: The present invention relates to novel sulfamoyl-phenyl-ureido compounds having the formula (I) or a physiologically acceptable salt or derivative thereof which are suitable for the therapy of infections caused by protozoa and in particular uncomplicated or severe malaria caused by plasmodia.
Abstract: The present invention relates to amide and urea derivatives of heteroaryl-substituted diazatricycloalkanes, pharmaceutical compositions including the compounds, methods of preparing the compounds, and methods of treatment using the compounds. More specifically, the methods of treatment involve modulating the activity of the ?7 nAChR subtype by administering one or more of the compounds to treat or prevent disorders mediated by the ?7 nAChR subtype. The diazatricycloalkanes typically consist of a 1-azabicyclooctane fused to pyrrolidine ring. The substituent heteroaryl groups are 5- or 6-membered ring heteroaromatics, such as 3-pyridinyl and 5-pyrimidinyl moieties, which are attached directly to the diazatricycloalkane. The secondary nitrogen of the pyrrolidine moiety is substituted with an arylcarbonyl (amide type derivative) or an arylaminocarbonyl (N-arylcarbamoyl) (urea type derivative) group.
Type:
Application
Filed:
April 7, 2010
Publication date:
August 5, 2010
Applicant:
Targacept, Inc.
Inventors:
Anatoly Mazurov, Lan Miao, Jozef Klucik
Abstract: The present invention provides methods for treating neurological diseases and disorders. Compounds that replace or enhance the function of SMN or alleviate or reduce a phenotype of cells with low SMN protein levels are provided. Screening methods and kits for identifying such compounds also are provided.
Abstract: The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
Type:
Application
Filed:
September 8, 2008
Publication date:
August 5, 2010
Inventors:
Tony Siu, Jonathan Young, Michael Altman, Alan Northrup, Matthew Katcher, Ellalahewage Sathyajith Kumarasinghe, Ekaterina Kozina, Scott Peterson, Matthew Childers
Abstract: The present invention relates to 4,5-ring annulated indole derivatives of formula (I), compositions comprising at least one 4,5-ring annulated indole derivatives, and methods of using the 4,5-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient, wherein ring Z of formula (I), is cyclohexyl, cyclohexenyl, 6-membered heterocycloalkyl, 6-membered heterocycloalkenyl, 6-membered aryl or 6-membered heteroaryl, wherein R1, R2, R3, R6, R7 and R10 are as described herein.
Type:
Application
Filed:
December 17, 2007
Publication date:
August 5, 2010
Applicant:
SCHERING CORPORATION
Inventors:
Gopinadhan N. Anilkumar, Yueheng Jiang, Stuart B. Rosenblum, Srikanth Venkatraman, Francisco Velazquez, Neng-Yang Shih, F. George Njoroge, Joseph A. Kozlowski
Abstract: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.
Type:
Grant
Filed:
April 18, 2005
Date of Patent:
August 3, 2010
Assignee:
PTC Therapeutics, Inc.
Inventors:
Young-Choon Moon, Liangxian Cao, Nadarajan Tamilarasu, Hongyan Qi, Soongyu Choi, William Joseph Lennox, Donald Thomas Corson, Seongwoo Hwang, Thomas Davis
Abstract: Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.
Type:
Application
Filed:
March 19, 2010
Publication date:
July 29, 2010
Applicant:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Inventors:
Asitha ABEYWARDANE, Craig Andrew MILLER, Tina Marie MORWICK, Neil MOSS, Matthew Russell NETHERTON, Roger John SNOW, Ji WANG, Jiang-Ping WU, Zhaoming XIONG
Abstract: It is an objective of the present invention to provide a safe and highly effective hypertension-ameliorating agent. The present invention provides a hypertension-ameliorating agent, comprising a compound represented by general formula (I) (wherein R1, R2, and R3 are the same as or different from each other, and each represents lower alkyl, lower alkenyl, lower alkynyl, aralkyl, araryl, phenyl, or a hydrogen atom) or a salt thereof as an active ingredient.
Type:
Application
Filed:
September 7, 2007
Publication date:
July 29, 2010
Applicants:
KYOWA HAKKO BIO CO., LTD., MITSUBISHI GAS CHEMICAL COMPANY, INC.
Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with kinases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.
Type:
Application
Filed:
February 18, 2010
Publication date:
July 29, 2010
Applicant:
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors:
Qing Dong, Bheema R. Paraselli, Nicholas Scorah, Michael B. Wallace, Jeffrey A. Stafford
Abstract: Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety.
Type:
Application
Filed:
January 12, 2010
Publication date:
July 22, 2010
Inventors:
WU DU, WILLIAM K. HAGMANN, SHUWEN HE, ZHONG LAI, SHRENIK K. SHAH, QUANG T. TRUONG
Abstract: Tricyclic nitrogen-containing compounds of Formula (I) or pharmaceutically acceptable salts, solvates or N-oxides thereof: compositions containing them, their use in the treatment of tuberculosis, and methods for the preparation of such compounds.
Type:
Application
Filed:
June 19, 2008
Publication date:
July 22, 2010
Inventors:
Lluis Ballell-Pages, David Barros-Aguirre, Julia Castro-Pichel, Modesto Jesus Remuinan-Blanco, Jose Maria Fiandor-Roman
Abstract: Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety.
Type:
Application
Filed:
July 15, 2008
Publication date:
July 22, 2010
Inventors:
Peter H. Dobbelaar, Wu Du, Liangqin Guo, William K. Hagmann, Shuwen He, Tianying Jian, Jian Liu, Ravi P. Nargund, Alexander Pasternak, Shrenik K. Shah, Quang T. Truong, Zhixiong Ye, James Deliureficio, Raman Bakshi
Abstract: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.
Type:
Application
Filed:
March 2, 2010
Publication date:
July 15, 2010
Inventors:
Young-Choon Moon, Liangxian Cao, Nadarajan Tamilarasu, Hongyan Qi, Soongyu Choi, William Joseph Lennox, Donald Thomas Corson, Seongwoo Hwang, Thomas Davis
Abstract: The invention provides compositions and methods for treating, preventing, delaying the onset, and/or delaying the development of a disease or condition for which the activation, differentiation, and/or proliferation of one or more cell types is beneficial. These compositions and methods include, for example, a hydrogenated pyrido[4,3-b]indole such as dimebon and/or a cell that has been incubated with a hydrogenated pyrido[4,3-b]indole such as dimebon. In some embodiments, the compositions and methods also include a growth factor and/or an anti-cell death compound. The invention also provides methods of activating a cell, promoting the differentiation of a cell, and/or promoting the proliferation of a cell by incubating the cell with one or more hydrogenated pyrido[4,3-b]indoles or pharmaceutically acceptable salts thereof. In some embodiments, the cell is also incubated with one or more growth factors and/or anti-cell death compounds.
Abstract: The invention presents methods of identifying small molecule compounds that are activators of tumor suppressor protein p53 pathway, and its associated family members p63 and p73, function. The invention is further drawn to methods of killing tumor cells and treating cancers or other conditions requiring activation of the p53 family member pathways and DNA damage response pathways with the small molecules.
Abstract: The present application is generally directed to compounds, compositions and methods of combination therapy for the treatment of neoplastic disorders.
Type:
Application
Filed:
January 7, 2010
Publication date:
July 8, 2010
Inventors:
Denis Drygin, Kenna Anderes, Caroline B. Ho, Joshua R. Bliesath, Christopher B. Proffitt, Sean O'Brien, William G. Rice
Abstract: The present invention provides a method of inducing cleavage of amyloid precursor protein to produce an approximately 17 kilodalton carboxy-terminal fragment of amyloid precursor protein in a subject, the method comprising administering a heterocyclic compound or a pharmaceutically acceptable salt, hydrate or prodrug thereof to a subject in need thereof, wherein the approximately 17 kilodalton fragment includes the carboxyterminal amino acid sequence of amyloid precursor protein and amyloid-beta amino acid sequence. Also provided is a screening method for identifying compounds induce cleavage of amyloid precursor protein to produce the approximately 17 kilodalton carboxy-terminal fragment of amyloid precursor protein.
Type:
Application
Filed:
December 15, 2009
Publication date:
July 1, 2010
Inventors:
Kim Nicholas Green, Tilman Oltersdorf, Eckard Weber
Abstract: The present invention provides methods and compounds for regulating fat metabolism and achieving fat homeostasis in a subject. Methods and compound for regulating body weight, reducing body fat, and inducing weight loss are also provided, as are methods and compounds for treating or preventing obesity and for preventing or treating conditions associated with altered fat metabolism including, e.g., obesity, diabetes, atherosclerosis, etc.
Type:
Application
Filed:
October 19, 2009
Publication date:
July 1, 2010
Applicant:
FibroGen, Inc.
Inventors:
Patrick D. Fourney, Volkmar Guenzler-Pukall, Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Todd W. Seeley